FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007244598> ?p ?o ?g. }

• W2007244598 endingPage "146" @default.
• W2007244598 startingPage "141" @default.
• W2007244598 abstract "Metastatic melanoma treatment remains disappointing, and a combined approach by chemotherapy and immunotherapy might increase the response rates through a synergistic action. Accordingly, a clinical trial using oral temozolomide (TMZ) and subcutaneous PEG-interferon α-2b (PEG) in patients with metastatic melanoma was designed to determine the maximal tolerated dosage of both drugs and the antitumoral response. A multicenter, prospective, phase I/II study was conducted in 31 metastatic melanoma patients, without cerebral metastasis. Dose escalation was performed according to the modified continual reassessment method scale and resulted in four cohorts of patients: TMZ 150 mg/m2 5 days/week each 4 weeks and PEG 0.5 μg/kg/week – TMZ 150 mg/m2 5 days/week and PEG 1.0 μg/kg/week – TMZ 200 mg/m2 5 days/week and PEG 0.5 μg/kg/week – TMZ 200 mg/m2 5 days/week and PEG 1.0 μg/kg/week. Patients received a maximum of six cycles. Thirty-three patients were enroled in this study: one in the first dose level, one in the second one, 18 in the third one and 11 in the fourth one. At level 4, four of 11 patients experienced dose-limiting toxicity and four nondose-limiting toxicity; toxicity was mainly hematologic (grade IV thrombocytopenia). An objective response was observed in five patients (two complete response and three partial response) receiving level 3 or 4 of treatment. The disease remained stable in three patients, and six of 31 patients were alive 24 months after enrolment. The association of oral TMZ with subcutaneous PEG in metastatic melanoma displayed an unacceptable hematological toxicity with the dosages of 200 mg/m2 5 days/week and 1 μg/week, respectively. At a lower level, this treatment was effective and deserves further investigations to define its indications in metastatic melanoma patients." @default.
• W2007244598 created "2016-06-24" @default.
• W2007244598 creator A5002644565 @default.
• W2007244598 creator A5014376121 @default.
• W2007244598 creator A5064052929 @default.
• W2007244598 creator A5066869362 @default.
• W2007244598 creator A5072616070 @default.
• W2007244598 creator A5079290076 @default.
• W2007244598 creator A5085647218 @default.
• W2007244598 creator A5087445295 @default.
• W2007244598 date "2008-04-01" @default.
• W2007244598 modified "2023-10-18" @default.
• W2007244598 title "Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study" @default.
• W2007244598 cites W1489896780 @default.
• W2007244598 cites W174200917 @default.
• W2007244598 cites W1917632054 @default.
• W2007244598 cites W1982193912 @default.
• W2007244598 cites W2001495454 @default.
• W2007244598 cites W2002288639 @default.
• W2007244598 cites W2006990152 @default.
• W2007244598 cites W2019465287 @default.
• W2007244598 cites W2066966314 @default.
• W2007244598 cites W2076108528 @default.
• W2007244598 cites W2076904060 @default.
• W2007244598 cites W2081797247 @default.
• W2007244598 cites W2086256043 @default.
• W2007244598 cites W2098405842 @default.
• W2007244598 cites W2104788624 @default.
• W2007244598 cites W2110429401 @default.
• W2007244598 cites W2119925221 @default.
• W2007244598 cites W2147322164 @default.
• W2007244598 cites W2245369264 @default.
• W2007244598 doi "https://doi.org/10.1097/cmr.0b013e3282f6309c" @default.
• W2007244598 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18337651" @default.
• W2007244598 hasPublicationYear "2008" @default.
• W2007244598 type Work @default.
• W2007244598 sameAs 2007244598 @default.
• W2007244598 citedByCount "10" @default.
• W2007244598 countsByYear W20072445982013 @default.
• W2007244598 countsByYear W20072445982014 @default.
• W2007244598 countsByYear W20072445982017 @default.
• W2007244598 countsByYear W20072445982018 @default.
• W2007244598 countsByYear W20072445982020 @default.
• W2007244598 countsByYear W20072445982021 @default.
• W2007244598 crossrefType "journal-article" @default.
• W2007244598 hasAuthorship W2007244598A5002644565 @default.
• W2007244598 hasAuthorship W2007244598A5014376121 @default.
• W2007244598 hasAuthorship W2007244598A5064052929 @default.
• W2007244598 hasAuthorship W2007244598A5066869362 @default.
• W2007244598 hasAuthorship W2007244598A5072616070 @default.
• W2007244598 hasAuthorship W2007244598A5079290076 @default.
• W2007244598 hasAuthorship W2007244598A5085647218 @default.
• W2007244598 hasAuthorship W2007244598A5087445295 @default.
• W2007244598 hasConcept C10138342 @default.
• W2007244598 hasConcept C126322002 @default.
• W2007244598 hasConcept C141071460 @default.
• W2007244598 hasConcept C143998085 @default.
• W2007244598 hasConcept C162324750 @default.
• W2007244598 hasConcept C188816634 @default.
• W2007244598 hasConcept C2776694085 @default.
• W2007244598 hasConcept C2777389519 @default.
• W2007244598 hasConcept C2777658100 @default.
• W2007244598 hasConcept C2780964509 @default.
• W2007244598 hasConcept C29730261 @default.
• W2007244598 hasConcept C31760486 @default.
• W2007244598 hasConcept C502942594 @default.
• W2007244598 hasConcept C54400483 @default.
• W2007244598 hasConcept C71924100 @default.
• W2007244598 hasConcept C90924648 @default.
• W2007244598 hasConceptScore W2007244598C10138342 @default.
• W2007244598 hasConceptScore W2007244598C126322002 @default.
• W2007244598 hasConceptScore W2007244598C141071460 @default.
• W2007244598 hasConceptScore W2007244598C143998085 @default.
• W2007244598 hasConceptScore W2007244598C162324750 @default.
• W2007244598 hasConceptScore W2007244598C188816634 @default.
• W2007244598 hasConceptScore W2007244598C2776694085 @default.
• W2007244598 hasConceptScore W2007244598C2777389519 @default.
• W2007244598 hasConceptScore W2007244598C2777658100 @default.
• W2007244598 hasConceptScore W2007244598C2780964509 @default.
• W2007244598 hasConceptScore W2007244598C29730261 @default.
• W2007244598 hasConceptScore W2007244598C31760486 @default.
• W2007244598 hasConceptScore W2007244598C502942594 @default.
• W2007244598 hasConceptScore W2007244598C54400483 @default.
• W2007244598 hasConceptScore W2007244598C71924100 @default.
• W2007244598 hasConceptScore W2007244598C90924648 @default.
• W2007244598 hasIssue "2" @default.
• W2007244598 hasLocation W20072445981 @default.
• W2007244598 hasLocation W20072445982 @default.
• W2007244598 hasOpenAccess W2007244598 @default.
• W2007244598 hasPrimaryLocation W20072445981 @default.
• W2007244598 hasRelatedWork W1843585357 @default.
• W2007244598 hasRelatedWork W1991803873 @default.
• W2007244598 hasRelatedWork W2057024276 @default.
• W2007244598 hasRelatedWork W2085691690 @default.
• W2007244598 hasRelatedWork W2097691839 @default.
• W2007244598 hasRelatedWork W2148037622 @default.
• W2007244598 hasRelatedWork W2259293861 @default.
• W2007244598 hasRelatedWork W2357678202 @default.

• next